Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Fosun International Limited
  6. News
  7. Summary
    656   HK0656038673

FOSUN INTERNATIONAL LIMITED

(656)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fosun International : Participates in the Inaugural Asia Summit on Global Health, Actively Promoting Collaborations in Global Health

11/26/2021 | 04:50am EST
Fosun Participates in the Inaugural Asia Summit on Global Health, Actively Promoting Collaborations in Global Health
Release Time:2021-11-24Author:Source: Pageviews:

"In the future construction of the health systems, we should focus on three aspects: first, the development of rapid, large-scale and low-cost testing capabilities; second, the easy access to vaccination; third, medical institutions must be well-equipped to quickly respond to infectious diseases such as COVID-19."

On 24 November, the inaugural Asia Summit on Global Health (ASGH) co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC) opened today at the Hong Kong Convention and Exhibition Centre (HKCEC) in a hybrid format, offering both online and in-person participation. Chen Qiyu, Co-CEO of Fosun International who was one of the speakers at the panel discussion under the plenary session themed "Shaping a Resilient and Sustainable Future", shared his view on the short-term and long-term development of healthcare industry in the post-pandemic world and how Fosun is helping to create a more resilient, sustainable and inclusive future.

Co-operate and Embrace Changes

Themed "Shaping a Resilient and Sustainable Future", the summit aims to bring together medical and health professionals and business leaders from all over the world, promoting medical innovations, investment exchanges and investment cooperation. More than 70 speakers, including senior government health officials from around the world, representatives of international organisations, medical research experts as well as investors and business leaders, shared their insights from the perspectives of healthcare, finance and technology, and examined the latest technological developments and investment opportunities in the healthcare sector.

Dr Peter K N Lam, Chairman of the HKTDC delivered a welcome speech and Carrie Lam, Chief Executive of the HKSAR gave an opening speech to kick off the summit. Carrie Lam said that the Government of the HKSAR has invested more than HK$130 billion over the past four years to promote the innovation and technology industry. It has established InnoHK innovative Hong Kong R&D platform in the Hong Kong Science Park, while the Hong Kong-Shenzhen Innovation and Technology Park the Lok Ma Chau Loop in cooperation with Shenzhen will be completed in 2024, with the primary goal of developing healthcare technologies.

The COVID-19 pandemic has led to structural changes in the healthcare industry, rapid innovation and adaptation are much needed, including the application of digital platforms, research and development of new drugs, and unprecedented public-private partnerships to build more resilient health systems. In this battle against the COVID-19, concerted efforts by the Government and enterprises have resulted in innovative breakthroughs in the development, clinical trial, approval, and marketing of COVID-19 vaccines and therapeutic drugs.

When speaking about the global cooperation during the pandemic, Chen Qiyu said that, Fosun has reached an mRNA vaccine cooperation with Germany's BioNTech at the beginning of the pandemic. "It was very early at that time, and we didn't know whether the vaccine would be put into use. Based on the SARS experience, the pandemic ended before the vaccine research and development was completed. However, we still firmly believed that we should explore the most advanced field in the world. Later on, we were very pleased to learn that this vaccine is being developed and marketed rapidly worldwide."

Innovation to Shape the Future

The COVID-19 outbreak in 2020 has highlighted the need for joint efforts to promote technological innovation in the global healthcare industry, so as to shape a resilient and sustainable future. In addition, the ever-changing demographic profile in Asia is driving market's demand for healthcare technologies and solutions, thus creating immense investment opportunities for the healthcare industry.

Chen Qiyu pointed out that Fosun's rapid establishment of the vaccine cooperation at the beginning of the pandemic was made possible thanks to Fosun's persistent investment and cooperation in world's leading pharmaceutical technology and accumulation of experience in globalization over the past ten years.

Over the years, Fosun has always adhered to the globalization strategy, gradually enhancing its competitiveness in the world: Fosun Pharma began to establish a pharmaceutical innovation and research team in the U.S. in 2009, was listed in Hong Kong in 2012, established its first overseas M&A project, Alma Lasers in 2013, established joint ventures with Intuitive Surgical and Kite Pharma successively in 2016 and 2017, acquired controlling stake in the Indian pharmaceutical company Gland Pharma, and partnered with Germany's BioNTech to develop mRNA-based vaccines in response to the pandemic in 2020, etc.

In the future, Fosun will continue to create innovative blockbuster products in the field of health, exert greater efforts in areas such as innovative R&D, BD, production and operation, and commercialization. On the one hand, it will put forward development plan in cutting-edge areas and innovate blockbuster products through diversified models such as cooperative development, license introduction, and investment. On the other hand, it will also focus on maximizing product value by strengthening overseas market sales and foreign licensing in overseas markets.

Chen Qiyu pointed out that human societies are entering an era of healthcare technology boom, the R&D process of small molecule drugs, large molecule drugs, antibody drugs, cell drugs, and mRNA technology is accelerating. "As the precision of future treatments is getting higher, there will be more opportunities for product R&D. For instance, there will be huge breakthroughs and developments in the field of oncology based on the integration of current technologies such as small molecule drugs, antibody drugs, cell therapy, and genes. This is also what Fosun must do: develop an innovation platform that encompass the entire chain from diagnosis to technologies, such as small molecules, large molecules, cells, nucleic acids, etc."

Regarding the construction of the health systems in the post-epidemic era, Chen Qiyu said that we should focus on three aspects: first, the development of rapid, large-scale and low-cost testing capabilities; second, the easy access to vaccination; third, medical institutions must be well-equipped to quickly respond to infectious diseases such as COVID-19.

"Facing the future, we need to introduce reforms in two areas. First, the reform of medical technology and continuous innovation; second, the reform of healthcare processes and systems, we need to integrate new technologies, digital technology, mobile medical equipment, and personal information management, etc." Chen Qiyu said, "Fosun hopes to leverage on the current achievements of technological innovation to tackle more health problems, letting more people live past 90 years old, 100 years old and even 121 years old."

Previous:Already the First ArticleNext:Lanvin Group Unveils New Brand Identity

Disclaimer

Fosun International Limited published this content on 24 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 November 2021 09:49:06 UTC.


ę Publicnow 2021
All news about FOSUN INTERNATIONAL LIMITED
01/18FOSUN INTERNATIONAL : Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Di..
PU
01/13FOSUN INTERNATIONAL : Ranks Fourth in “Hurun China Private Companies SDG Readiness 1..
PU
01/12FOSUN INTERNATIONAL : Hospital da Luz Lisboa with Maximum Rating of Clinical Excellence
PU
01/10FOSUN'S INTELLIGENT MANUFACTURING : China's First Privately-owned High-speed Railway Start..
PU
01/06FOSUN INTERNATIONAL : MSCI ESG ratingupgraded to AA
PU
01/05GUO GUANGCHANG NEW YEAR'S SHARING : Believe in the Power of Perseverance
PU
2021FOSUN INTERNATIONAL : Shede Gala Concert Spreads Love and Charity Through Music
PU
2021ONE FOSUN CSR WEEK : Fosun Global Philanthropic Campaigns Sending Warmth and Love to All
PU
2021ONE FOSUN CSR WEEK : Fosuners Bring Warmth to the World with Global Philanthropic Campaign..
PU
2021FOSUN INTERNATIONAL : Receives “ESG Communications Award” at the PR Newswire N..
PU
More news
Analyst Recommendations on FOSUN INTERNATIONAL LIMITED
More recommendations
Financials
Sales 2021 155 B 24 445 M 24 445 M
Net income 2021 12 012 M 1 895 M 1 895 M
Net Debt 2021 126 B 19 871 M 19 871 M
P/E ratio 2021 4,92x
Yield 2021 4,67%
Capitalization 59 746 M 9 426 M 9 425 M
EV / Sales 2021 1,20x
EV / Sales 2022 1,13x
Nbr of Employees 78 000
Free-Float 27,2%
Chart FOSUN INTERNATIONAL LIMITED
Duration : Period :
Fosun International Limited Technical Analysis Chart | 656 | HK0656038673 | MarketScreener
Technical analysis trends FOSUN INTERNATIONAL LIMITED
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 7,19 CNY
Average target price 10,65 CNY
Spread / Average Target 48,2%
EPS Revisions
Managers and Directors
Qi Yu Chen Co-Chief Executive Officer & Executive Director
Xiao Liang Xu Co-Chief Executive Officer & Executive Director
Ping Gong Chief Financial Officer & Executive Director
Hou Lin Zhang Co-Chief Financial Officer & Senior Vice President
Li Gang Zhang Co-CFO & GM-Financial Management
Sector and Competitors
1st jan.Capi. (M$)
FOSUN INTERNATIONAL LIMITED4.99%9 426
ALLIANZ SE6.77%102 705
CHUBB LIMITED-0.67%82 733
MARSH & MCLENNAN COMPANIES, INC.-8.99%79 294
ZURICH INSURANCE GROUP LTD8.19%70 512
BAJAJ FINSERV LIMITED-0.43%34 978